Follow Altria to never miss an important update.
Jefferies set a price target of $60 for the stock, which is about 11 percent lower than where it trades today. This is more conservative than the average analyst target of $70. While the company is successfully raising cigarette prices to cover falling sales volumes, analysts are closely watching how fast its newer nicotine pouches and vapes can grow to fill the gap. This target suggests a more cautious view on that transition than the rest of the market currently holds.
Source: Jefferies
The U.S. Food and Drug Administration is expected to announce new measures to speed up its review of vaping products and nicotine pouches. For years, the agency has faced a massive backlog of applications, leaving many products in a legal gray area while they wait for a formal decision.
This is a helpful shift for Altria as it tries to move away from traditional cigarettes. The company is betting its future on products like on! nicotine pouches and NJOY e-vapor, but these rely on clear government approval to win over long-term customers and secure shelf space. A faster, more predictable process helps Altria scale these newer, high-margin businesses more quickly.
Source: Reuters
Altria has filed a lawsuit against the Food and Drug Administration (FDA), the government agency that regulates tobacco and nicotine products. While the court records do not yet show exactly which rules the company is fighting, these legal battles usually center on how the agency approves new products or restricts existing ones.
This is a common move for Altria as it tries to protect its core business while launching new products like nicotine pouches and vapor. The company relies on a steady regulatory environment to keep its high profit margins, so any shift in FDA rules can affect how easily it can sell its products or raise prices.
Source: Reuters
The Food and Drug Administration authorized the sale of three new JUUL2 e-cigarette products. The agency, which regulates tobacco and nicotine to protect public health, stated these products may offer a lower-risk alternative for adults who currently smoke traditional cigarettes.
This is a helpful development for the broader nicotine market. While Altria sold its stake in Juul years ago to buy rival NJOY, a more predictable FDA approval process for vapor products makes it easier for the entire industry to transition away from cigarettes. It suggests a clearer path forward for the smoke-free products that Altria is betting its future on.
Source: Reuters
Altria increased its board size from 10 to 11 members and elected Steven W. Presley to the board on August 27. Mr. Presley will also serve on the committees responsible for executive pay, innovation, and finance. This is a routine addition of an independent director, which is a person not employed by the company who helps oversee management on behalf of shareholders.
Source: 8-K filing
Management has a long history of hitting its targets by a penny or two, showing they have a tight grip on the business and set bars they know they can clear.
| Expectation | |
|---|---|
| EPS | $1.51 |
| Revenue | $5.31B |